WO2015099201A1 - Composition contenant des nanobulles, et son utilisation - Google Patents
Composition contenant des nanobulles, et son utilisation Download PDFInfo
- Publication number
- WO2015099201A1 WO2015099201A1 PCT/JP2015/050073 JP2015050073W WO2015099201A1 WO 2015099201 A1 WO2015099201 A1 WO 2015099201A1 JP 2015050073 W JP2015050073 W JP 2015050073W WO 2015099201 A1 WO2015099201 A1 WO 2015099201A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- cells
- agent
- water
- cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 119
- 239000002101 nanobubble Substances 0.000 title claims abstract description 48
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000001737 promoting effect Effects 0.000 claims abstract description 23
- 239000001257 hydrogen Substances 0.000 claims abstract description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 13
- 239000001301 oxygen Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 230000010261 cell growth Effects 0.000 claims abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 238000005138 cryopreservation Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 72
- 239000002609 medium Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 27
- 230000002438 mitochondrial effect Effects 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 210000003470 mitochondria Anatomy 0.000 claims description 12
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 9
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000007952 growth promoter Substances 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 239000003501 hydroponics Substances 0.000 claims description 5
- 239000003761 preservation solution Substances 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 111
- 230000000694 effects Effects 0.000 description 36
- 239000007789 gas Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000010586 diagram Methods 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 229930182536 Antimycin Natural products 0.000 description 13
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 13
- 230000035622 drinking Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 239000003651 drinking water Substances 0.000 description 12
- 235000020188 drinking water Nutrition 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000002407 ATP formation Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- DEAFEFSHUVGNFC-JTQLQIEISA-N (2s)-6-amino-2-(hexanoylamino)hexanoic acid Chemical compound CCCCCC(=O)N[C@H](C(O)=O)CCCCN DEAFEFSHUVGNFC-JTQLQIEISA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- -1 More preferably Chemical compound 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000001988 somatic stem cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019583 umami taste Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QEUHXYPYKZKYFW-ZQHUEGGHSA-N (2e,4e)-13-hydroperoxyoctadeca-2,4-dienoic acid Chemical compound CCCCCC(OO)CCCCCCC\C=C\C=C\C(O)=O QEUHXYPYKZKYFW-ZQHUEGGHSA-N 0.000 description 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 1
- JDSRHVWSAMTSSN-BSZOFBHHSA-N 13-HPODE Chemical compound CCCCCC(OO)\C=C\C=C/CCCCCCCC(O)=O JDSRHVWSAMTSSN-BSZOFBHHSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000233513 Brassica perviridis Species 0.000 description 1
- 235000008744 Brassica perviridis Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 240000005856 Lyophyllum decastes Species 0.000 description 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 210000002453 autonomic neuron Anatomy 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000001813 extracellular matrix secreting cell Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000044446 human CD46 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000019607 umami taste sensations Nutrition 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
- A23P30/40—Foaming or whipping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dentistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Environmental Sciences (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Hydroponics (AREA)
Abstract
[Problème] La présente invention concerne une composition contenant des nanobulles contenant de l'hydrogène, de l'oxygène et de l'azote, et son utilisation. [Solution] Composition contenant en tant que matière active des nanobulles ayant un diamètre de 30 µm ou moins et contenant 0,45 à 0,55 ppm d'hydrogène, 10 à 12,5 ppm d'oxygène et 7 à 8 ppm d'azote. L'invention concerne aussi une composition d'activation des mitochondries, un agent favorisant la croissance cellulaire, un liquide de conservation des cellules ou un liquide de cryoconservation contenant cette composition, et un procédé pour utilisation de cette composition, de cet agent ou de ce liquide. Elle concerne aussi un aliment ou une boisson, ou une matière première pour aliment ou pour boisson, produit par utilisation de cette composition.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201580001311.2A CN105593363A (zh) | 2013-12-27 | 2015-01-05 | 含纳米气泡的组合物及其用途 |
| US15/193,176 US20170056438A1 (en) | 2014-10-17 | 2016-06-27 | Nanobubble-containing composition and use thereof |
| HK16112319.1A HK1223975A1 (zh) | 2013-12-27 | 2016-10-26 | 含納米氣泡的組合物及其用途 |
| US16/161,192 US20190046563A1 (en) | 2013-12-27 | 2018-10-16 | Nanobubble-containing composition and use thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013273610 | 2013-12-27 | ||
| JP2013-273610 | 2013-12-27 | ||
| JP2014-212676 | 2014-10-17 | ||
| JP2014212676 | 2014-10-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/193,176 Continuation US20170056438A1 (en) | 2013-12-27 | 2016-06-27 | Nanobubble-containing composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015099201A1 true WO2015099201A1 (fr) | 2015-07-02 |
Family
ID=53479037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2015/050073 WO2015099201A1 (fr) | 2013-12-27 | 2015-01-05 | Composition contenant des nanobulles, et son utilisation |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2016063804A (fr) |
| CN (1) | CN105593363A (fr) |
| HK (1) | HK1223975A1 (fr) |
| WO (1) | WO2015099201A1 (fr) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017126647A1 (fr) * | 2016-01-21 | 2017-07-27 | 国立大学法人大阪大学 | Procédé de culture de cellules |
| WO2017154855A1 (fr) * | 2016-03-06 | 2017-09-14 | アクア・ゼスト株式会社 | Composition favorisant la régénération osseuse et appareil favorisant la régénération osseuse |
| WO2019230972A1 (fr) * | 2018-05-31 | 2019-12-05 | 学校法人 愛知医科大学 | Composition, composition de stockage cellulaire, composition de culture cellulaire, formulation cellulaire, procédé de production d'un objet contenant des microbulles, procédé de stockage cellulaire, procédé de culture cellulaire et procédé de production de formulation cellulaire |
| CN111972399A (zh) * | 2020-08-06 | 2020-11-24 | 温州医科大学 | 维持肝细胞活性的保存液 |
| JP2021069973A (ja) * | 2019-10-29 | 2021-05-06 | 学校法人 愛知医科大学 | 微小気泡含有電解質液の製造方法および微小気泡含有電解質液の調製に用いる微小気泡含有溶媒の製造方法 |
| JP2021070641A (ja) * | 2019-10-30 | 2021-05-06 | 浩平 池田 | 心停止後の自己心拍再開後の生存率改善剤 |
| JPWO2019230973A1 (ja) * | 2018-05-31 | 2021-07-26 | 学校法人 愛知医科大学 | 生体材料保存組成物、生体材料の保存方法、生体材料の生産方法、移植材料、および移植方法 |
| WO2022019152A1 (fr) * | 2020-07-20 | 2022-01-27 | 学校法人 愛知医科大学 | Composition pour la culture d'entretien indifférenciée de cellules pluripotentes, milieu pour la culture d'entretien indifférenciée de cellules pluripotentes, procédé de culture d'entretien à l'état indifférencié de cellules pluripotentes, et procédé de production de cellules pluripotentes |
| CN114469758A (zh) * | 2022-01-25 | 2022-05-13 | 中国科学院上海应用物理研究所 | 一种小粒径纳米气泡水及其制备方法以及应用 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102162400B1 (ko) * | 2016-05-13 | 2020-10-06 | 시그마 테크놀로지 유겐가이샤 | 생체 투여 가능한 수용액 및 그 제조 방법 |
| JP6129395B1 (ja) * | 2016-10-29 | 2017-05-17 | 誠一 荒木 | ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンｂ２製剤 |
| JP7149053B2 (ja) * | 2017-04-25 | 2022-10-06 | 株式会社田中金属製作所 | 糖尿病予防又は改善用液状物 |
| CN110227363A (zh) * | 2018-03-06 | 2019-09-13 | 四季洋圃生物机电股份有限公司 | 多功能超微气泡水实施方法及其制造装置 |
| KR20210136177A (ko) * | 2018-05-30 | 2021-11-16 | 가부시키가이샤 아쿠아솔루션 | 흰가루병의 방제 방법 |
| JP7041895B2 (ja) * | 2018-10-02 | 2022-03-25 | 株式会社ファーベスト | ミトコンドリア活性化材料、ミトコンドリア活性化組成物およびミトコンドリア活性化方法 |
| JP6890353B2 (ja) * | 2019-03-26 | 2021-06-18 | ＭｉＺ株式会社 | 分子状水素を含む腎臓疾患の腎機能改善のための組成物 |
| WO2020261464A1 (fr) * | 2019-06-26 | 2020-12-30 | 武田薬品工業株式会社 | Procédé de transfection |
| JPWO2021064995A1 (fr) * | 2019-10-04 | 2021-04-08 | ||
| WO2021070908A1 (fr) * | 2019-10-08 | 2021-04-15 | 岩谷産業株式会社 | Composition pour congéler des cellules, procédé de congélation de cellules, procédé de mise en culture de cellules et kit de congélation de cellules |
| CN111919990A (zh) * | 2020-08-04 | 2020-11-13 | 上海华鹿环保技术中心 | 一种纯天然纳米气泡保鲜水及其制备方法 |
| CN113209847A (zh) * | 2021-06-11 | 2021-08-06 | 同济大学 | 无菌纳米气泡水及其制备方法和应用 |
| CN114600872A (zh) * | 2022-04-13 | 2022-06-10 | 西安北光医学生物技术有限公司 | 一种细胞、组织或器官的抗损伤保存的方法及保存系统 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
| JP2009082903A (ja) * | 2007-09-16 | 2009-04-23 | Sgk Kk | マイクロバブル生成装置。 |
| JP2009195889A (ja) * | 2008-02-25 | 2009-09-03 | Opt Creation:Kk | ナノバブル液体製造装置及びナノバブル液体 |
| JP2010075180A (ja) * | 2008-09-01 | 2010-04-08 | Hiroyuki Tanaka | Ｎｋ活性増強剤およびその利用 |
| WO2010126908A1 (fr) * | 2009-04-27 | 2010-11-04 | Revalesio Corporation | Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète |
| JP2011078371A (ja) * | 2009-10-09 | 2011-04-21 | Tomotaka Marui | 細胞変化を促進する微小気泡含有組成物、およびその微小気泡含有組成物を製造する装置、ならびに微小気泡含有組成物を用いた細胞変化促進方法。 |
| WO2011139478A2 (fr) * | 2010-04-30 | 2011-11-10 | H R D Corporation | Application à cisaillement élevé utilisée dans une thérapie médicale |
| JP2011244779A (ja) * | 2010-05-31 | 2011-12-08 | Tomotaka Marui | 微小気泡を含有する液体の組成物、および、微小気泡を含有する組成物の製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5120998B2 (ja) * | 2006-09-06 | 2013-01-16 | 国立大学法人 東京医科歯科大学 | 組織、細胞又は臓器の保存液 |
| JP4921332B2 (ja) * | 2007-11-29 | 2012-04-25 | 株式会社Ｒｅｏ研究所 | 窒素ナノバブル水の製造方法 |
| JP4594996B2 (ja) * | 2008-05-02 | 2010-12-08 | 株式会社 シンワ | 微細気泡混合次亜塩素酸ナトリウム希釈液を用いた食品殺菌方法及び装置 |
-
2015
- 2015-01-05 WO PCT/JP2015/050073 patent/WO2015099201A1/fr active Application Filing
- 2015-01-05 CN CN201580001311.2A patent/CN105593363A/zh active Pending
- 2015-01-05 JP JP2015000580A patent/JP2016063804A/ja active Pending
-
2016
- 2016-10-26 HK HK16112319.1A patent/HK1223975A1/zh unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
| JP2009082903A (ja) * | 2007-09-16 | 2009-04-23 | Sgk Kk | マイクロバブル生成装置。 |
| JP2009195889A (ja) * | 2008-02-25 | 2009-09-03 | Opt Creation:Kk | ナノバブル液体製造装置及びナノバブル液体 |
| JP2010075180A (ja) * | 2008-09-01 | 2010-04-08 | Hiroyuki Tanaka | Ｎｋ活性増強剤およびその利用 |
| WO2010126908A1 (fr) * | 2009-04-27 | 2010-11-04 | Revalesio Corporation | Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète |
| JP2011078371A (ja) * | 2009-10-09 | 2011-04-21 | Tomotaka Marui | 細胞変化を促進する微小気泡含有組成物、およびその微小気泡含有組成物を製造する装置、ならびに微小気泡含有組成物を用いた細胞変化促進方法。 |
| WO2011139478A2 (fr) * | 2010-04-30 | 2011-11-10 | H R D Corporation | Application à cisaillement élevé utilisée dans une thérapie médicale |
| JP2011244779A (ja) * | 2010-05-31 | 2011-12-08 | Tomotaka Marui | 微小気泡を含有する液体の組成物、および、微小気泡を含有する組成物の製造方法 |
Non-Patent Citations (1)
| Title |
|---|
| TOSHIAKI ABE ET AL.: "Micro Bubble o Riyo shita Saibo Baiyo", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 112, 2008, pages 197 * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10954487B2 (en) | 2016-01-21 | 2021-03-23 | Osaka University | Cell culturing method |
| JPWO2017126647A1 (ja) * | 2016-01-21 | 2018-11-15 | 国立大学法人大阪大学 | 細胞の培養方法 |
| WO2017126647A1 (fr) * | 2016-01-21 | 2017-07-27 | 国立大学法人大阪大学 | Procédé de culture de cellules |
| WO2017154855A1 (fr) * | 2016-03-06 | 2017-09-14 | アクア・ゼスト株式会社 | Composition favorisant la régénération osseuse et appareil favorisant la régénération osseuse |
| CN108778293A (zh) * | 2016-03-06 | 2018-11-09 | 水活力株式会社 | 骨再生促进用组合物及骨再生促进装置 |
| CN112218940A (zh) * | 2018-05-31 | 2021-01-12 | 学校法人爱知医科大学 | 组合物、细胞保存组合物、细胞培养组合物、细胞制剂、包含微小气泡的对象物的制造方法、细胞的保存方法、细胞的培养方法和细胞制剂的制造方法 |
| EP3795674A4 (fr) * | 2018-05-31 | 2022-05-11 | Aichi Medical University | Composition, composition de stockage cellulaire, composition de culture cellulaire, formulation cellulaire, procédé de production d'un objet contenant des microbulles, procédé de stockage cellulaire, procédé de culture cellulaire et procédé de production de formulation cellulaire |
| JP7449539B2 (ja) | 2018-05-31 | 2024-03-14 | 学校法人 愛知医科大学 | 生体材料保存組成物、生体材料の保存方法、生体材料の生産方法、移植材料、および移植方法 |
| WO2019230972A1 (fr) * | 2018-05-31 | 2019-12-05 | 学校法人 愛知医科大学 | Composition, composition de stockage cellulaire, composition de culture cellulaire, formulation cellulaire, procédé de production d'un objet contenant des microbulles, procédé de stockage cellulaire, procédé de culture cellulaire et procédé de production de formulation cellulaire |
| JPWO2019230972A1 (ja) * | 2018-05-31 | 2021-07-15 | 学校法人 愛知医科大学 | 組成物、細胞保存組成物、細胞培養組成物、細胞製剤、微小気泡を含む対象物の製造方法、細胞の保存方法、細胞の培養方法、および細胞製剤の製造方法 |
| JPWO2019230973A1 (ja) * | 2018-05-31 | 2021-07-26 | 学校法人 愛知医科大学 | 生体材料保存組成物、生体材料の保存方法、生体材料の生産方法、移植材料、および移植方法 |
| JP7382602B2 (ja) | 2018-05-31 | 2023-11-17 | 学校法人 愛知医科大学 | 組成物、細胞保存組成物、細胞培養組成物、細胞製剤、微小気泡を含む対象物の製造方法、細胞の保存方法、細胞の培養方法、および細胞製剤の製造方法 |
| EP3794943A4 (fr) * | 2018-05-31 | 2022-05-11 | Aichi Medical University | Composition de conservation de biomatériau, procédé de conservation de biomatériau, procédé de production de biomatériau, matériau de transplantation et méhode de transplantation |
| JP2021069973A (ja) * | 2019-10-29 | 2021-05-06 | 学校法人 愛知医科大学 | 微小気泡含有電解質液の製造方法および微小気泡含有電解質液の調製に用いる微小気泡含有溶媒の製造方法 |
| WO2021084869A1 (fr) * | 2019-10-29 | 2021-05-06 | 学校法人 愛知医科大学 | Procédé de fabrication d'électrolyte contenant des microbulles et procédé de fabrication de solvant contenant des microbulles destiné à être utilisé dans la préparation d'un électrolyte contenant des microbulles |
| JP2021070641A (ja) * | 2019-10-30 | 2021-05-06 | 浩平 池田 | 心停止後の自己心拍再開後の生存率改善剤 |
| WO2022019152A1 (fr) * | 2020-07-20 | 2022-01-27 | 学校法人 愛知医科大学 | Composition pour la culture d'entretien indifférenciée de cellules pluripotentes, milieu pour la culture d'entretien indifférenciée de cellules pluripotentes, procédé de culture d'entretien à l'état indifférencié de cellules pluripotentes, et procédé de production de cellules pluripotentes |
| CN111972399B (zh) * | 2020-08-06 | 2021-11-30 | 温州医科大学 | 维持肝细胞活性的保存液 |
| CN111972399A (zh) * | 2020-08-06 | 2020-11-24 | 温州医科大学 | 维持肝细胞活性的保存液 |
| CN114469758A (zh) * | 2022-01-25 | 2022-05-13 | 中国科学院上海应用物理研究所 | 一种小粒径纳米气泡水及其制备方法以及应用 |
| CN114469758B (zh) * | 2022-01-25 | 2024-02-20 | 中国科学院上海应用物理研究所 | 一种小粒径纳米气泡水及其制备方法以及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016063804A (ja) | 2016-04-28 |
| CN105593363A (zh) | 2016-05-18 |
| HK1223975A1 (zh) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015099201A1 (fr) | Composition contenant des nanobulles, et son utilisation | |
| US20190046563A1 (en) | Nanobubble-containing composition and use thereof | |
| Cornish et al. | Consumption of seaweeds and the human brain | |
| Tarazona-Díaz et al. | Watermelon juice: potential functional drink for sore muscle relief in athletes | |
| CN106255421B (zh) | 大蒜发酵组合物的制造方法及大蒜发酵组合物 | |
| CN105724892B (zh) | 促使干细胞增生及增加端粒酶活性的食物补充品 | |
| CN109730309A (zh) | 健脑益智安神缓解压力益智仁复合多肽营养素及制备方法 | |
| JP7032855B2 (ja) | 時計遺伝子の発現を変化させるための組成物 | |
| CN108402472B (zh) | 一种女用蚕蛹提取生物蛋白 | |
| CA2615257A1 (fr) | Preparation fonctionnelle | |
| JP6735224B2 (ja) | アストロサイトのグルコース代謝活性化剤 | |
| MXPA05010042A (es) | Composiciones de farmacos en micro-agregados, composiciones bioafectadoras, composiciones para el tratamiento corporal, medios de cultivo, alimentos y bebidas. | |
| RU2504222C2 (ru) | Пищевой продукт, обладающий лечебно-профилактическими свойствами | |
| CN104026589B (zh) | 一种肽化酵素及其制备方法 | |
| JP2018070568A (ja) | 非アルコール性脂肪性肝疾患治療又は予防剤及び非アルコール性脂肪性肝疾患予防用食品 | |
| US20050129789A1 (en) | Drugs including anticancer agents and immunopotentiators and health foods and drinks | |
| RU2414227C1 (ru) | Иммуномодулятор для выращивания бройлеров и способ его применения | |
| JP7286335B2 (ja) | 骨密度改善用食品組成物、骨密度改善剤、前駆骨芽細胞増殖用食品組成物、骨分化促進用食品組成物、骨強化用食品組成物、抗骨粗鬆症用食品組成物、前駆骨芽細胞増殖剤、骨分化促進剤、骨強化剤、抗骨粗鬆症剤、骨密度改善剤の製造方法、前駆骨芽細胞増殖剤の製造方法、骨分化促進剤の製造方法、骨強化剤の製造方法及び抗骨粗鬆症剤の製造方法 | |
| CN103555527B (zh) | 蛇肽保健酒及其制备方法 | |
| CN100392058C (zh) | 含纳米sod的果酒及其制备方法 | |
| Kazemi et al. | Evaluation the effect of royal jelly on the growth of two members of gut microbiota; Bacteroides fragillis and Bacteroides thetaiotaomicron. | |
| WO2016206363A1 (fr) | Utilisation d'oligopeptide de ginseng de jilin dans la préparation d'un produit alimentaire anti-oxydant ou d'un produit alimentaire de soins de santé | |
| KR20150032223A (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 적혈구계 세포 분화 또는 증식 촉진용 조성물 | |
| US20040076618A1 (en) | Placental preparation having antitumor activity | |
| JP7465551B2 (ja) | Ｎｋ細胞活性化組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15731237 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15731237 Country of ref document: EP Kind code of ref document: A1 |